Navigation Links
GSK Does Not Option XL784 for Further Development
Date:1/18/2008

SOUTH SAN FRANCISCO, Calif., Jan. 18 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today announced that GlaxoSmithKline (GSK) has decided not to exercise its option to license XL784 for further development and commercialization. Exelixis previously announced that XL784 failed to meet its primary endpoint in a phase 2 trial in patients with diabetic nephropathy. Although the data in one subgroup were encouraging, Exelixis believes that the exciting data being generated by other compounds to which GSK has an option under its collaboration agreement with Exelixis made it unlikely that GSK would use one of its one or two remaining options to choose XL784. As a result of GSK's decision, Exelixis has the right to develop and commercialize XL784 either independently or in collaboration with third parties, subject to payment to GSK of a 3% royalty on sales of any products incorporating the compound.

XL784 is a potent inhibitor of the ADAM-10 and MMP-2 metalloprotease enzymes, targets of significant interest because of their important role in renal fibrosis and impairment. Although the phase 2 trial in patients with diabetic nephropathy did not meet its primary endpoint, there were encouraging data from the trial. The compound was well tolerated, and the subgroup of patients who were being treated with maximal doses of ACE inhibitors or ARBs did appear to show a substantial benefit from XL784, although this difference did not reach statistical significance. Exelixis itself does not intend to invest further in the development of this drug, but will seek a partner with which to take the compound forward.

XL784 is part of Exelixis' clinical development financing arrangement with Symphony Evolution, Inc.

About Exelixis <
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
2. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
3. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
4. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
5. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
6. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
9. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. St. Jude Defines Eye Cancer Genes Role in Retinal Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global ... Depository Trust Company (DTC) has made their final ... Chill on the Company,s stock effective December 15, ... common stock for depository and book entry transfer ... Company is now once again fully "DTC Eligible", ...
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... LOS ANGELES , Dec. 17, 2014 /PRNewswire/ ... that the US Patent and Trademark Office (USPTO) ... candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting ... glioblastoma. The claims of US Patent No. 8,871,211, ... treating neural cancer by administering a dendritic cell ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Inc. (NYSE: LDR ), a recognized leader ... and high quality medical consumable accessories, today reported financial results ... Fiscal 2012 Second Quarter Highlights ... prior year period. , Gross profit grew 11 percent ...
... Inc. (NASDAQ: UPI ), a medical device ... for the treatment of voiding dysfunctions, announced today that ... President and CFO, will present the Company,s business strategy ... JMP Securities Research Conference at 12:30 pm PT on Monday, ...
Cached Medicine Technology:Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 12Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 13Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 14Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 15Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 16Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 17Uroplasty to Present at the 11th Annual JMP Securities Research Conference 2
(Date:12/21/2014)... Viejo, California (PRWEB) December 21, 2014 ... Studios have announced a new intro plugin for Final ... to animate pictures, videos, logos, and more with absolute ... “We’ve given our users the tools needed to easily ... ProMotion allows Final Cut Pro X users to animate ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation ... and Whittier offices. The Hope for the Holidays Toy Drive ... and their families during the holiday season. This year, the ... children between both offices. This event continues to be successful ... service team, store managers and assistant managers came out and ...
(Date:12/20/2014)... 21, 2014 BambooIndustry.com is ... the business has announced its bamboo flooring promotion ... best material from certified suppliers, and offers the ... worldwide. In the current promotion, all customers can ... when they say they know BambooIndustry.com from press ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 An improving ... sector have benefited the Massage Services industry ... characteristics of industry products, the anticipated 1.0% annualized increase ... has provided consumers with the means to afford additional ... received a massage in a given year has declined ...
(Date:12/20/2014)... 2014 The print component of Healthy ... distribution of approximately 160,000 copies and an estimated readership ... a vast social media strategy and across a network ... the digital version of the campaign, click here ... with the ladies of CTV’s The Social. Lainey ...
Breaking Medicine News(10 mins):Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2
... Mich., March 24 Perrigo Company,(Nasdaq: PRGO ... CEO Joseph,C. Papa will present at the 12th ... March 25, at 2:05 p.m. (ET) at the,Grand ... Company is a leading global healthcare supplier that ...
... discuss risk factors with their doctors, SCHAUMBURG, ... known that,psoriasis, a chronic skin condition characterized by ... have a significant negative impact on a,patient,s overall ... especially severe psoriasis, is linked with a number ...
... PAUL, Minn., March 24 Children,s,Hospitals and Clinics ... Morath, RN, chief operating officer and vice president ... National Quality Forum (NQF), a,private, not-for-profit membership organization ... healthcare quality measurement and,reporting., Morath will be ...
... JAMA Editor-in-Chief Catherine D. DeAngelis, M.D., M.P.H., and ... about a recent court ruling regarding litigation involving ... that significantly threatened the integrity of our peer ... Pfizer, Inc. had issued subpoenas last year to ...
... the University of Washington have uncovered how the bacterium ... superbug strains, resists our body,s natural defenses against infection. ... the March 21 issue of Science, could lead to ... Ferric Fang, UW professor of laboratory medicine and microbiology, ...
... Compliance Corp.,(OTC Bulletin Board: SCOM) ("Sharps" or the ... quantity generators of,medical waste, announced today the appointment ... President of Operations. Mr. Aladwani joins Sharps,effective immediately ... of medical devices, where he served as Vice ...
Cached Medicine News:Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 3Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 4Health News:Children's Hospitals and Clinics of Minnesota COO, Julie Morath, Appointed to National Quality Forum Committee 2Health News:Scientists uncover how superbug Staph aureus resists our natural defenses 2Health News:Sharps Compliance Corp. Announces Appointment of Al Aladwani as its Senior Vice President of Operations 2Health News:Sharps Compliance Corp. Announces Appointment of Al Aladwani as its Senior Vice President of Operations 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: